{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:51:18Z","timestamp":1791492678331,"version":"4.3.4"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T00:00:00Z","timestamp":1789862400000},"content-version":"vor","delay-in-days":19,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016579","name":"Amgen K.K","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016579","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-cardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jjcc.2026.09.006","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T15:23:31Z","timestamp":1790004211000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Contemporary lipid management and achievement of LDL-C targets after acute myocardial infarction in Japan: Insights from the K-ACTIVE registry"],"prefix":"10.1016","author":[{"given":"Norihiko","family":"Kamioka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Ohno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Ikari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaka","family":"Iso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Akashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junya","family":"Ako","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Ebina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kouichi","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Shibata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoshi","family":"Hibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Fukui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Michishita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jjcc.2026.09.006_bb0005","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1093\/eurheartj\/ehaa1011","article-title":"Low-density lipoprotein cholesterol reduction and statin intensity in myocardial infarction patients and major adverse outcomes: a Swedish nationwide cohort study","volume":"42","author":"Schubert","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jjcc.2026.09.006_bb0010","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jjcc.2026.09.006_bb0015","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1016\/j.jacc.2009.09.010","article-title":"Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome. PCI-PROVE IT: a PROVE IT-TIMI 22 pravastatin or atorvastatin evaluation and infection therapy-thrombolysis I","volume":"54","author":"Gibson","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2026.09.006_bb0020","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s12928-024-00994-7","article-title":"Drug intervention as an emerging concept for secondary prevention in patients with coronary disease","volume":"39","author":"Minami","year":"2024","journal-title":"Cardiovasc Interv Ther"},{"key":"10.1016\/j.jjcc.2026.09.006_bb0025","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid lowering with statins after acute coronary syndromes","volume":"350","author":"Cannon","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2026.09.006_bb0030","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","article-title":"2016 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"37","author":"Catapano","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jjcc.2026.09.006_bb0035","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"73","author":"Grundy","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2026.09.006_bb0040","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association task force on practice guidelines","volume":"63","author":"Stone","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2026.09.006_bb0045","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1016\/j.jacc.2024.11.009","article-title":"ACC\/AHA\/ACEP\/NAEMSP\/SCAI guideline for the management of patients with acute coronary syndromes","volume":"85","author":"Rao","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2026.09.006_bb0050","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jjcc.2026.09.006_bb0055","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1253\/circj.CJ-25-0365","article-title":"Global low-density lipoprotein cholesterol targets for patients with acute coronary syndrome \u2014 current guidelines and clinical pathways \u2014","volume":"90","author":"Minami","year":"2026","journal-title":"Circ J"},{"key":"10.1016\/j.jjcc.2026.09.006_bb0060","article-title":"Temporal trends of high-intensity statin therapy among veterans treated with percutaneous coronary intervention","volume":"7","author":"Abdulhak","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jjcc.2026.09.006_bb0065","doi-asserted-by":"crossref","first-page":"641","DOI":"10.5551\/jat.GL2022","article-title":"Japan atherosclerosis society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2022","volume":"31","author":"Okamura","year":"2024","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.jjcc.2026.09.006_bb0070","doi-asserted-by":"crossref","first-page":"336","DOI":"10.5551\/jat.65908","article-title":"Lipid management for secondary prevention in atherosclerotic cardiovascular disease: a scoping review and scientific report","volume":"33","author":"Tanaka","year":"2026","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.jjcc.2026.09.006_bb0075","doi-asserted-by":"crossref","first-page":"e618","DOI":"10.1161\/CIR.0000000000000617","article-title":"Fourth universal definition of myocardial infarction (2018)","volume":"138","author":"Thygesen","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2026.09.006_bb0080","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.jjcc.2022.02.007","article-title":"Impact of atrial fibrillation and the clinical outcomes in patients with acute myocardial infarction from the K-ACTIVE registry","volume":"79","author":"Mori","year":"2022","journal-title":"J Cardiol"},{"key":"10.1016\/j.jjcc.2026.09.006_bb0085","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1016\/j.jcin.2020.08.026","article-title":"Early initiation of evolocumab markedly reduces low-density lipoprotein cholesterol levels after myocardial infarction","volume":"13","author":"Okada","year":"2020","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.jjcc.2026.09.006_bb0090","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.5551\/jat.63940","article-title":"Achievement rates for low-density lipoprotein cholesterol goals in patients at high risk of atherosclerotic cardiovascular disease in a real-world setting in Japan","volume":"30","author":"Mitani","year":"2023","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.jjcc.2026.09.006_bb0095","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.5551\/jat.59543","article-title":"Lipid management and 2-year clinical outcomes in Japanese patients with acute coronary syndrome: explore-j","volume":"28","author":"Nakamura","year":"2021","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.jjcc.2026.09.006_bb0100","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1093\/ehjcvp\/pvaf004","article-title":"Impact of a personalized, strike early and strong lipid-lowering approach on low-density lipoprotein-cholesterol levels and cardiovascular outcome in patients with acute myocardial infarction","volume":"11","author":"Patti","year":"2025","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.jjcc.2026.09.006_bb0105","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jacc.2021.10.035","article-title":"Coronary atherosclerotic plaque regression: JACC state-of-the-art review","volume":"79","author":"Dawson","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2026.09.006_bb0110","first-page":"939","volume":"11","author":"Krychtiuk","year":"2022","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"10.1016\/j.jjcc.2026.09.006_bb0115","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12196390","article-title":"National trends in the use of state-reimbursed lipid-lowering medications in Latvia (2012\u22122021)","volume":"12","author":"Praskilevics","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.jjcc.2026.09.006_bb0120","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1186\/s12944-025-02786-1","article-title":"Lipid-lowering therapy in Switzerland: time trends in utilization and cost, 2015\u20132023","volume":"24","author":"Wolf","year":"2025","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.jjcc.2026.09.006_bb0125","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jacc.2023.05.042","article-title":"Combination lipid-lowering therapy in patients undergoing percutaneous coronary intervention","volume":"82","author":"Lee","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2026.09.006_bb0130","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2026.09.006_bb0135","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.jacc.2015.05.065","article-title":"Impact of dual lipid-lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention","volume":"66","author":"Tsujita","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2026.09.006_bb0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2023.1156081","article-title":"Medication adherence with fixed-dose versus free-equivalent combination therapies: systematic review and meta-analysis","volume":"14","author":"Wei","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jjcc.2026.09.006_bb0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fcvm.2025.1461416","article-title":"Treatment adherence, persistence, and effectiveness of fixed dose combination versus free combination therapy of rosuvastatin\u2013ezetimibe as a lipid-lowering therapy","volume":"12","author":"Samnaliev","year":"2025","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.jjcc.2026.09.006_bb0150","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1007\/s12325-024-02916-8","article-title":"Differential adherence to free and single-pill combination of rosuvastatin\/ezetimibe: findings from a real-world analysis in Italy","volume":"41","author":"Perez de Isla","year":"2024","journal-title":"Adv Ther"},{"key":"10.1016\/j.jjcc.2026.09.006_bb0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ehjopen\/oeae074","article-title":"A real-world analysis of adherence, biochemical outcomes, and healthcare costs in patients treated with rosuvastatin\/ezetimibe as single-pill combination vs. free combination in Italy","volume":"4","author":"Zambon","year":"2024","journal-title":"Eur Heart J Open"},{"key":"10.1016\/j.jjcc.2026.09.006_bb0160","doi-asserted-by":"crossref","first-page":"19","DOI":"10.5551\/jat.RV16004","article-title":"Racial differences in the cholesterol-lowering effect of statin","volume":"24","author":"Naito","year":"2017","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.jjcc.2026.09.006_bb0165","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jjcc.2024.05.011","article-title":"Prognostic significance of baseline low-density lipoprotein cholesterol in patients undergoing coronary revascularization; a report from the CREDO-Kyoto registry","volume":"84","author":"Kanenawa","year":"2024","journal-title":"J Cardiol"},{"key":"10.1016\/j.jjcc.2026.09.006_bb0170","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2026.09.006_bb0175","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1001\/jamacardio.2023.5155","article-title":"Impact of bempedoic acid on total cardiovascular events: a prespecified analysis of the CLEAR outcomes randomized clinical trial","volume":"9","author":"Nicholls","year":"2024","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jjcc.2026.09.006_bb0180","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1001\/jama.2016.16951","article-title":"Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial","volume":"316","author":"Nicholls","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jjcc.2026.09.006_bb0185","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.jjcc.2025.04.002","article-title":"Effect of PCSK9 inhibitor usage on coronary endothelial dysfunction in patients with hypercholesterolemia after coronary stenting: the CuVIC-2 trial","volume":"86","author":"Akiyama","year":"2025","journal-title":"J Cardiol"},{"key":"10.1016\/j.jjcc.2026.09.006_bb0190","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1093\/eurheartj\/ehu505","article-title":"Cardiovascular risk in post-myocardial infarction patients: Nationwide real world data demonstrate the importance of a long-term perspective","volume":"36","author":"Jernberg","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jjcc.2026.09.006_bb0195","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1253\/circj.CJ-25-0083","article-title":"Characteristics of patients with acute coronary syndrome and lipid management status insights from the optimal therapy for all Kagoshima acute coronary syndrome (OK-ACS) registry","volume":"89","author":"Kanda","year":"2025","journal-title":"Circ J"},{"key":"10.1016\/j.jjcc.2026.09.006_bb0200","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1253\/circj.CJ-24-0714","article-title":"Current status and prospects of regional collaborative pathways for management of acute coronary syndrome in Japan \u2014 a nationwide survey \u2014","volume":"89","author":"Minami","year":"2025","journal-title":"Circ J"},{"key":"10.1016\/j.jjcc.2026.09.006_bb0205","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1253\/circj.CJ-24-0338","article-title":"Impact of implementation of a region-wide low-density lipoprotein cholesterol management clinical pathway for the secondary prevention of acute myocardial infarction","volume":"88","author":"Kurobe","year":"2024","journal-title":"Circ J"}],"container-title":["Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0914508726001887?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0914508726001887?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:40:35Z","timestamp":1791492035000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0914508726001887"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":41,"alternative-id":["S0914508726001887"],"URL":"https:\/\/doi.org\/10.1016\/j.jjcc.2026.09.006","relation":{},"ISSN":["0914-5087"],"issn-type":[{"value":"0914-5087","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Contemporary lipid management and achievement of LDL-C targets after acute myocardial infarction in Japan: Insights from the K-ACTIVE registry","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jjcc.2026.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Japanese College of Cardiology. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}